Data / Form D filings / Lexaria Bioscience Corp.
Lexaria Bioscience Corp.: Form D filings
Lexaria Bioscience Corp., a biotechnology company in Kelowna, British Columbia, Canada, filed 15 Form D notices with the SEC between 2016 and 2026. The latest, on September 21, 2026, reports $113,492 sold of a $113,492 offering to 3 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 100 - 740 MCCURDY ROAD, Kelowna, British Columbia, Canada, V1X 2
- Phone
- (250) 765-6424
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Nevada
- Revenue range
- $5,000,001 - $25,000,000
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1348362
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 21, 2026 | New notice | $113,492 | $113,492 | 3 | Sep 9, 2026 | sec.gov | |
| Dec 19, 2025 | New notice | $3,500,004 | $3,500,004 | 5 | Dec 16, 2025 | sec.gov | |
| Oct 1, 2025 | New notice | $4,000,000 | $4,000,000 | 5 | Sep 29, 2025 | sec.gov | |
| Oct 16, 2024 | New notice | $5,000,000 | $5,000,000 | 1 | Oct 16, 2024 | sec.gov | |
| May 2, 2024 | New notice | $364,629 | $364,629 | 1 | Apr 30, 2024 | sec.gov | |
| Feb 16, 2024 | New notice | $3,600,003 | $3,600,003 | 2 | Feb 16, 2024 | sec.gov | |
| Oct 4, 2023 | New notice | $1,569,780 | $1,569,780 | 1 | Oct 3, 2023 | sec.gov | |
| Dec 20, 2021 | New notice | $1,200,000 | $1,200,000 | 1 | Dec 16, 2021 | sec.gov | |
| Jul 27, 2021 | New notice | $85,000 | $85,000 | 1 | Jul 27, 2021 | sec.gov | |
| Jul 8, 2020 | New notice | $100,000 | $100,000 | 1 | Jun 30, 2020 | sec.gov | |
| May 13, 2020 | New notice | $2,039,228 | $2,039,228 | 21 | May 6, 2020 | sec.gov | |
| Nov 19, 2019 | New notice | $2,357,594 | $492,500 | $1,865,094 | 5 | Nov 13, 2019 | sec.gov |
| Nov 13, 2019 | New notice | $180,000 | $180,000 | 1 | Nov 5, 2019 | sec.gov | |
| Nov 15, 2018 | New notice | $310,000 | $310,000 | 3 | Oct 31, 2018 | sec.gov | |
| Sep 13, 2016 | New notice | $108,500 | $108,500 | 6 | Aug 31, 2016 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Christopher Bunka | Director | |
| John Docherty | Executive Officer, Director | |
| Richard Christopher | Executive Officer, Director | |
| Michael Shankman | Executive Officer | |
| Nicholas Baxter | Director | |
| William Edward McKechnie | Director | |
| ALBERT REESE | Director | |
| Bal Bhullar | Director |
Every Form D from the week of Sep 21, 2026 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Lexaria Bioscience Corp. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.